NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy ?
Source: Newsfilter
Trading Transition: NKGen Biotech, Inc. will begin trading on the OTC Markets under ticker symbols "NKGN" for common stock and "NKGNW" for warrants starting March 5, 2025, after being delisted from Nasdaq due to non-compliance with listing requirements.
Clinical Developments: The company has completed its quarterly reporting obligations and is focused on enrolling participants in a Phase 2a Alzheimer's trial, with preliminary results expected by the end of 2025, while also maintaining compliance with SEC reporting requirements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
